Pooled analyses of clinical trials involving pembrolizumab monotherapy in patients with PD-L1-positive advanced NSCLC reported a longer overall survival (OS) and superior safety profiles compared to standard chemotherapy in older patients with PD-L1 TPS ≥ 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.